OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 

PRESS RELEASES

Rockville, MD - April 30, 2014 - OriGene Technologies (Rockville, MD), the industry’s largest supplier of gene-centric research tools, launches a new product line of gene-knockout kits using CRISPR technologies. The new products provide a complete solution for researchers to knock out a human gene at the chromosomal level. (Full Press Release)
ROCKVILLE, MD -- Feb 26, 2014 – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, announced today that it has acquired BioCheck, Inc., a provider of innovative immunodiagnostic test kits and custom immunoassay development for the world-wide health care and research markets.. (Full Press Release)
ROCKVILLE, MD--(Jan 30, 2014) – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays.. (Full Press Release)
Rockville, MD. May 30th, 2013 - Scientists from Peking University, China and OriGene Technologies jointly published that multiple lineage specifier genes can replace OCT4 and SOX2 during reprogramming, the core regulators of cell pluripotency.. (Full Press Release)
Rockville, MD – April 8, 2013 – OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. (Full Press Release)
Rockville, MD – March 21, 2013 – OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China.. (Full Press Release)
ROCKVILLE, MD--(Jan7, 2013) – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies. (Full Press Release)
ROCKVILLE, MD; July 19th, 2012 – OriGene Technologies, Inc. and Canada’s Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation.. (Full Press Release)
ROCKVILLE, MD, March 20th – OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB™ brand.. (Full Press Release)
Rockville, MD - March 2012 - OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.. (Full Press Release)
Rockville, MD – July 28, 2011 – OriGene Technologies, Inc. a gene-centric life sciences company, today announced that through its July release, the TrueMAB™ monoclonal antibodies have reached the 3000 product milestone. (Full Press Release)
AACC Conference, Atlanta, GA and Rockville, MD July 24, 2011- OriGene Technologies, Inc., a gene-centric life sciences company known for its development cDNA clones, human full length proteins, antibodies, and other molecular tools for multiplex research introduces its major breakthrough technology High-Density Protein Microarray Chip for the quality control of its (TrueMAB™) monoclonal antibodies. (Full Press Release)
Rockville, Maryland —February 1st, 2011— OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.. (Full Press Release)
Rockville, MD – January 20, 2011 – OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. (Full Press Release)
Rockville, MD – Aug 12th, 2010 – OriGene Technologies, Inc., a gene-centric life sciences company, announces the acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business since 1999. (Full Press Release)
Rockville, MD – June 3, 2010 – OriGene Technologies, Inc., a leading gene-centric life sciences company, has announced the first of its kind launch of over 5,000 heavy isotope labeled human proteins as internal standards for SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry analyses. The announcement was made at the 2010 American Society for Mass Spectrometry conference in Salt Lake City, Utah.. (Full Press Release)
San Francisco, CA. & Rockville, MD, May 28 - Hitachi Software Engineering America, Ltd. (Hitachi Software) and OriGene Technologies, Inc. (OriGene) today announced a co-marketing agreement to jointly promote OriGene’s multiplex assays built on Luminex xMAP®/Bio-Plex technology and Hitachi Software’s MasterPlex® software suite for analysis and reporting of multiplex assay data. (Full Press Release)
Rockville, MD - May 18, 2010 - OriGene Technologies, Inc. with the support of Wuxi Biopharmaceutical R&D Outsourcing Services Park (China), will build one of the largest and most sophisticated monoclonal antibody production centers in the world in Wuxi, China. (Full Press Release)
Rockville, MD/Seattle, WA – May 11, 2010 – OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins.. (Full Press Release)
Rockville, MD – March 17, 2010 – OriGene Technologies, Inc., a leading gene-centric life sciences company announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. (Full Press Release)
Rockville, Maryland, March 15, 2010 - OriGene Technologies, Inc. and Essen Instruments Inc. today announced a strategic alliance to co-develop ion channel cell lines. (Full Press Release)
Rockville, Maryland, Nov. 9, 2009 – OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen™ (Over-expression Lysates) in the Human Protein Atlas program. . (Full Press Release)
Rockville, MD. Aug. 24, 2009 – OriGene Technologies, Inc. announces the release of 5,000 purified human proteins, representing the most comprehensive offering of human cell-produced human proteins.. (Full Press Release)
Rockville, MD. Jun. 29, 2009 – Ball State University Department of Biology offers a Biotechnology Certificate Program which prepares undergraduate and graduate students with in-demand research and laboratory skills for graduate school or in careers as a research associate. (Full Press Release)
Rockville, MD. Feb. 11, 2009 – OriGene establishes high throughput monoclonal antibody production outsourcing center in China. (Full Press Release)
Rockville, MD. Oct. 23, 2008 – OriGene Technologies, Inc. announces its flagship products, TrueORF cDNA clones, are available now in GFP (green fluorescence protein) vector, enabling easy transfection monitoring and protein expression. With this launch, over 25,000 human ORF (open reading frame) clones and 12,000 mouse ORF clones can be ordered in pCMV-tGFP vector.. (Full Press Release)
Rockville, MD. September 15, 2008 – OriGene Technologies, Inc. announces it has launched a new product line for antibody validation - VERIFY Tagged Antigen™ - a collection of tagged over-expression cell lysates to be used as Western blot standards. The offering covers 5,000 over-expressed human proteins, each with a built-in C-terminal Myc/DDK tag for easy expression verification and antibody validation. (Press Release). (Full Press Release)
Rockville, MD. May 2nd, 2008 Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi’s Sarcoma herpesvirus. The results are published in May 2nd issue of Cell, titled “Application of active and kinase-deficient kinome collection for identification of kinase regulating Hedgehog signaling”. (Press Release). (Full Press Release)
Rockville, MD. September 26, 2006 –Novartis scientists have published their use of OriGene’s TrueCloneTM full-length cDNA collection to identify novel activators of PGC-1atranscription. This work was recently published in the Journal Proceedings of the National Academy of Sciences titled “Transducer of regulated CREB-binding proteins (TORCs) induces PGC-1a transcription and mitochondrial biogenesis in muscle cells” (PNAS, September 26, 2006 vol. 103 no.39 14379-14384). PGC-1alpha is a co-activator of PPAR-gamma and regulator of adaptive thermogenesis. Novel activators like TORCs can serve as potential therapeutic targets to modulate mitochondrial function which is implicated in many human diseases.. (Full Press Release)
March 28, 2006 – OriGene Technologies Inc. announced that Genentech has purchased their TrueCloneTM Collection of full-length human cDNAs suitable for transfection and direct in vitro expression for internal research and development.. (Full Press Release)
March 13, 2006 – OriGene Technologies Inc. today announced that Bayer HealthCare AG has acquired access to OriGene’s collection of authentic full-length cDNA clones.. (Full Press Release)
October 17, 2005 – OriGene Technologies Inc. today announced they have entered into an agreement with Cytomyx Holdings, PLC to co-develop new tools to profile gene expression and biomarker validation in a range of human cancers. . (Full Press Release)
August 2, 2005 - OriGene Technologies Inc. today announced that Eisai London Research Laboratories has licensed OriGenes FlagArray platform for high-throughput drug target discovery. "We are pleased to formalize our relationship with OriGene, said Yukio Nishizawa, PhD, Director of Research for Eisai London Research Labs. We believe OriGenes FlagArray to be an innovative technology that will prove an excellent platform for use in our discovery programs.". (Full Press Release)
July 25, 2005 - OriGene Technologies Inc. today announced a collaboration with the laboratory of Dr. Brian Seed at the MGH to use OriGenes FlagArray platform for high-throughput functional analysis of genes. "OriGene has done a wonderful job in creating an outstanding collection of high quality cDNAs in a single expression vector, said Brian Seed, PhD, We believe OriGene's FlagArray will be an extremely useful resource to help us accelerate our understanding of the function and role of genes in biology in a high throughput and systematic manner.". (Full Press Release)
April 26, 2005 - OriGene Technologies Inc. today announced that Regeneron Pharmaceuticals has licensed a subscription based access to their TrueCloneTM Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses. "We are pleased to formalize our relationship with OriGene, said Drew Murphy, Vice President of Target Discovery for Regeneron. We believe that full-length cDNAs isolated from cDNA libraries are the most reliable source of authentic coding regions for our critical applications. The OriGene True Clone collection has proven to be an excellent source of full-length human cDNAs for use in Regeneron's protein expression and target validation platforms.". (Full Press Release)
February 15, 2005 - OriGene Technologies Inc. today announced that Novasite Pharmaceuticals has licensed a subscription access to their TrueCloneTM Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses. "We are pleased to formalize our relationship with OriGene. We have found their TrueClone collection to be the best answer to expanding needs within the pharmaceutical industry to access readily available full-length human cDNAs for multiple drug targets in a timely and reliable manner, said Juan Ballesteros, Chief Scientific Officer of Novasite. The OriGene TrueClone collection will complement our endogenously expressed receptor cell lines and jumpstart our programs to screen families of GPCRs for allosteric modulators." . (Full Press Release)
October 19, 2004 - OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement for a cancer target initially identified with OriGenes HTP-Rapid-ScanTM technology. MacroGenics has the exclusive right to develop compounds against the target under the terms of their collaboration and will focus on the development of therapeutic monoclonal antibody candidates to this molecule. In exchange, OriGene will be entitled to receive various option fees, milestones and royalty payments as the compounds are developed and commercialized.. (Full Press Release)
September 23, 2004 - OriGene Technologies Inc., a privately held company currently providing the worlds largest collection of 22,000 authentic full-length cDNA clones (TrueCloneTM), announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Human Genome Research Institute (NHGRI). . (Full Press Release)
Rockville, MD. August 10, 2004 - OriGene Technologies Inc. today announce that Structural Genomic Consortium located at Oxford University and University of Toronto has access to the TrueClone Collection of over 22,000 non-redundant full-length human cDNA clones for use in their structural genomics program.. (Full Press Release)
Rockville, MD. August 9, 2004 - OriGene Technologies Inc. announced Xantos Biomedicine in Germany has acquired access to their TrueClone Collection of non-redundant full-length human cDNA clones. Xantos uses its proprietary High-Throughput Cellular Screening Technology, XantoScreen and the full-length human clone collection to identify and functionaly validate novel targets.. (Full Press Release)
Rockville, MD. March 30, 2004 OriGene Technologies Inc. today announced the purchase of the TrueClone Collection of over 20,000 non-redundant full-length human cDNA clones by the RIKEN Protein Research Group (PRG) for use in their structural proteomics and related protein functional analysis programs.. (Full Press Release)
Rockville, MD. March 9, 2004 OriGene Technologies Inc. today announced the purchase of the TrueClone Collection of over 20,000 non-redundant full-length human cDNA clones by the Genomics Institute of the Novartis Research Foundation (GNF) for use in high-throughput discovery efforts. . (Full Press Release)
Rockville, MD. February 24, 2004 OriGene Technologies Inc today announced the addition of the NHR (Nuclear Hormone Receptor) CloneSet, a designated subset of 70 full-length nuclear hormone receptor cDNA clones, to their TrueClone Collection product line. . (Full Press Release)
Rockville, MD. December 10, 2003 OriGene Technologies Inc today announced the addition of the GPCR CloneSet, a designated subset of over 300 full-length human non-olfactory G protein-coupled receptors, to the TrueClone Collection product line. The GPCR CloneSet is the largest commercial cDNA source of this pharmaceutically important gene family, thus enabling a system biology approach to drug-potency, drug-toxicity and ligand identification studies. . (Full Press Release)
Rockville, MD. November 4, 2003 OriGene Technologies Inc today announced the addition of the Kinase CloneSet, a designated subset of over 500 full-length kinase cDNA clones, to their TrueClone Collection product line. The Kinase CloneSet approaches the predicted 518 putative genes in the Kinome (Manning, G. et al., Science 298:1912, 2002) and represents the largest commercial source of full-length human kinase genes. . (Full Press Release)
Rockville, MD. October 7, 2003 OriGene Technologies Inc today announced a research collaboration with Tanox Inc (NASDAQ TNOX) for the functional study of 2,000 full-length human cDNA clones encoding membrane bound proteins. Tanox will reserve the rights for therapeutic applications identified through this collaboration. OriGene will retain the rights for research and diagnostic reagent development. . (Full Press Release)

 

liner
Inc 5000 Healthcare Company Copyright © 2014 OriGene Technologies, Inc. All Rights Reserved. Legal Notices.
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 • 1.888.267.4436

Reproduction of any materials from this website is strictly forbidden without permission.

All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title